ArticleMagma (New York, N.Y.)2026
Hippocampal volume from T1 MRI as an atrophy biomarker: automated calculation and Scheltens' scale correlation.
Article in Magma (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveScheltens' discrete scale is widely used for assessing brain atrophy but has limitations in subjectivity and tracking patient progression over short periods. Automated brain volumetry offers a more objective imaging approach for diagnosing neurodegenerative diseases. This retrospective study aims to correlate Scheltens' scale assessments with hippocampal and cerebrum volumes measured by volBrain, enhancing patient care. MATERIALS AND
methodsThis study involved 106 participants, including healthy volunteers and patients with mild cognitive impairment, all scanned using a standardized MRI protocol. Two radiologists assessed medial temporal lobe atrophy, while volBrain automated the volumetric measurements. Reliability between raters was evaluated using the intra-class correlation coefficient and Kappa analysis. Shapiro-Wilk test performed to evaluate the normality of data distribution, Spearman's, Kruskal-Wallis, and Dunn's ad hoc tests used to compare the Scheltens' scale with volumetric data. Receiver operating characteristic analysis performed for the radiologist evaluations and ordinal logistic regression used to model the probability of Schelten's scores with relative hippocampal volumes.
resultsRaters had almost perfect agreement. Scheltens' scale correlations with hippocampus volumetric measurements were strongly significant, but correlations with cerebrum volumetric measurements were weak. Automated brain volumetric software presented 82% sensitivity and 100% specificity. Ordinal logistic regression presented overall model significance. DISCUSSION: This study suggests that hippocampus relative volume is a sensitive biomarker for atrophy evaluation toward an advanced, medial lobe atrophy scale, providing clinicians with a precise and objective tool.
Indexed as
Identifiers
41931256What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.